Skip to main content
. 2018 Nov 14;10(11):442. doi: 10.3390/cancers10110442

Figure 3.

Figure 3

Frequency of pathogenic and likely pathogenic variants in all analyzed genes (A), the family history status in the BRCA1 and BRCA2 mutation-positive individuals (B) and in the individuals heterozygous for the pathogenic or likely pathogenic variants in other breast/ovarian cancer susceptibility genes (C).